An observational study of alemtuzumab following fingolimod for multiple sclerosis

OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alem...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurol Neuroimmunol Neuroinflamm
Prif Awduron: Willis, Mark, Pearson, Owen, Illes, Zsolt, Sejbaek, Tobias, Nielsen, Christian, Duddy, Martin, Petheram, Kate, van Munster, Caspar, Killestein, Joep, Malmeström, Clas, Tallantyre, Emma, Robertson, Neil
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226279/
https://ncbi.nlm.nih.gov/pubmed/28101520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000320
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg